SH3BGRL2: A Potential Drug Target and Biomarker (G83699)

Target Name: SH3BGRL2

NCBI ID: G83699

SH3BGRL2

SH3BGRL2: A Potential Drug Target and Biomarker

SH3BGRL2, also known as Fovea-associated SH3 domain-binding protein, is a protein that has been identified using RNA-seq as highly expressed in the retina, and is primarily localized to the Fovea region of the retina, which is responsible for sharp, central vision. The SH3BGRL2 protein has been shown to play a role in the development and maintenance of retinal integrity, and is considered a potential drug target for several diseases, including neurodegenerative disorders.

The SH3BGRL2 protein is a member of the SH3 domain family, which is known for its ability to interact with various protein substrates, including phosphatidylinositol (PIP), a cell membrane phospholipid. The SH3 domain is a conserved region that is found in a variety of proteins, including SH3TFs (S/TIP and SH3-associated Tudor domain proteins), SHC1 (short for SH3-associated Calbindin-containing 1), and SH2D4 (SH3-associated p120).

SH3BGRL2 was first identified using RNA-seq as a highly expressed protein in the retina, with the highest expression levels observed in the Fovea region. The Fovea region is a critical area of the retina that is responsible for sharp, central vision, and is home to many of the photoreceptor cells that are responsible for transmitting information about the visual world to the brain. The SH3BGRL2 protein has been shown to play a role in the development and maintenance of retinal integrity, and is considered a potential drug target for several diseases, including neurodegenerative disorders.

One of the key challenges in studying the SH3BGRL2 protein is its high expression level in the retina, which can make it difficult to study. However, recent studies have provided new insights into the biology of the SH3BGRL2 protein. For example, researchers have shown that the SH3BGRL2 protein is associated with the development of age-related macular degeneration (AMD), a leading cause of blindness in the developed world. Additionally, studies have shown that the SH3BGRL2 protein is associated with the development of other diseases, including neurodegenerative disorders and multiple sclerosis.

In addition to its potential as a drug target, the SH3BGRL2 protein is also a potential biomarker for several diseases. For example, SH3BGRL2 has been shown to be associated with the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Additionally, the SH3BGRL2 protein has been shown to be associated with the development of other diseases, including cardiovascular disease and cancer. These findings suggest that the SH3BGRL2 protein may be a useful biomarker for several diseases, including neurodegenerative disorders.

In conclusion, SH3BGRL2 is a protein that has been identified as a potential drug target and biomarker. Its high expression level in the retina and its association with the development of several diseases make it a promising target for researchers to study. Further studies are needed to fully understand the role of the SH3BGRL2 protein in the development and maintenance of retinal integrity, as well as its potential as a drug target and biomarker.

Protein Name: SH3 Domain Binding Glutamate Rich Protein Like 2

The "SH3BGRL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3BGRL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets